AbCellera (ABCL) announced that it has entered into a multi-year, multi-target strategic collaboration with AbbVie (ABBV). The partnership will leverage AbCellera’s antibody discovery and development engine to deliver optimized development candidates for up to five targets selected by AbbVie across multiple indications. Under the terms of the agreement, AbbVie has the right to develop and commercialize therapeutic antibodies resulting from the collaboration. AbCellera will receive research payments and is eligible to receive downstream clinical and commercial milestone payments and royalties on net sales of products.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on ABCL:
- AbCellera initiated with a Buy at Goldman Sachs
- AbCellera, Rallybio enter pact for novel antibody-based therapeutics
- Bebtelovimab losing EUA has ‘limited impact’ on Piper model for AbCellera
- FDA announces bebtelovimab not currently authorized in any U.S. region
- AbCellera down 7% after FDA announces bebtelovimab not authorized in U.S.
